Literature DB >> 2237121

Enterobacter bacteremia in pediatric patients.

P G Gallagher1.   

Abstract

Enterobacter has emerged as an important human pathogen, particularly in sick, hospitalized patients. Previous reports of nonepidemic enterobacter bacteremia have focused on adult patients. In this report, the epidemiologic factors, clinical characteristics, treatment, and outcome for 33 patients with enterobacter bacteremia in a large children's hospital during a 5-year period are reviewed. The ratio of males to females was 1.2:1. The patients' ages ranged from 2 days to 24 years, and 18 patients were less than 18 months old. Twenty-two cases were nosocomially acquired; six were polymicrobial in nature. Significantly underlying conditions were present in 32 patients. The biliary tract and central venous catheters were the most common sources of bacteremia. Two-thirds of patients had preceding antibiotic therapy. The overall mortality was 24%; mortality attributable to enterobacter bacteremia was 18%. Statistically significant differences in mortality were associated with an age less than 18 months (P = .031) or thrombocytopenia (P = .017); presence of fever was of borderline significance (P = .098). Enterobacter bacteremia is an important cause of morbidity and mortality in pediatric patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2237121     DOI: 10.1093/clinids/12.5.808

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  11 in total

1.  Specificity of the high-mannose recognition site between Enterobacter cloacae pili adhesin and HT-29 cell membranes.

Authors:  Y T Pan; B Xu; K Rice; S Smith; R Jackson; A D Elbein
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

Review 2.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

3.  Plasmid-mediated resistance to expanded-spectrum cephalosporins among Enterobacter aerogenes strains.

Authors:  J D Pitout; K S Thomson; N D Hanson; A F Ehrhardt; P Coudron; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

4.  Beta-lactamases and detection of beta-lactam resistance in Enterobacter spp.

Authors:  J D Pitout; E S Moland; C C Sanders; K S Thomson; S R Fitzsimmons
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Temporal trends in Enterobacter species bloodstream infection: a population-based study from 1998-2007.

Authors:  M N Al-Hasan; B D Lahr; J E Eckel-Passow; L M Baddour
Journal:  Clin Microbiol Infect       Date:  2011-04       Impact factor: 8.067

6.  A case of bilateral endogenous Pantoea agglomerans endophthalmitis with interstitial lung disease.

Authors:  Susie Seok; Young Jun Jang; Seung Woo Lee; Ho Chang Kim; Gyoung Yim Ha
Journal:  Korean J Ophthalmol       Date:  2010-08-03

7.  Characterization of surface proteins of Cronobacter muytjensii using monoclonal antibodies and MALDI-TOF Mass spectrometry.

Authors:  Ziad W Jaradat; Abrar M Rashdan; Qotaiba O Ababneh; Saied A Jaradat; Arun K Bhunia
Journal:  BMC Microbiol       Date:  2011-06-25       Impact factor: 3.605

8.  Adhesive properties of Enterobacter sakazakii to human epithelial and brain microvascular endothelial cells.

Authors:  Jean-Philippe Mange; Roger Stephan; Nicole Borel; Peter Wild; Kwang Sik Kim; Andreas Pospischil; Angelika Lehner
Journal:  BMC Microbiol       Date:  2006-06-26       Impact factor: 3.605

Review 9.  Healthcare-associated infections in neonatal units: lessons from contrasting worlds.

Authors:  S Srivastava; N Shetty
Journal:  J Hosp Infect       Date:  2007-03-12       Impact factor: 3.926

10.  Isolation of Cronobacter spp. (formerly Enterobacter sakazakii) from infant food, herbs and environmental samples and the subsequent identification and confirmation of the isolates using biochemical, chromogenic assays, PCR and 16S rRNA sequencing.

Authors:  Ziad W Jaradat; Qotaiba O Ababneh; Ismail M Saadoun; Nawal A Samara; Abrar M Rashdan
Journal:  BMC Microbiol       Date:  2009-10-27       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.